Personalizing leukemia drug doses could boost treatment success
NCT ID NCT02896842
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This trial investigates whether adjusting the dose of imatinib (Gleevec) based on the drug's level in the blood can improve outcomes for people newly diagnosed with chronic phase chronic myeloid leukemia (CML). Participants whose imatinib blood level is low after 28 days are randomly assigned to either have their dose adjusted or continue the standard dose. The study aims to see if dose personalization leads to a higher rate of major molecular response at 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imatinib mesylate (Gleevec/Glivec)
- What this could lead to
- If successful, this could show that personalizing imatinib doses based on blood levels leads to better disease control for people with chronic myeloid leukemia.
- What could go wrong
- This is a mid-stage trial with a modest size, so results may not be conclusive. Dose adjustments could also increase side effects without improving outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Boulogne
Boulogne, France
-
CH Dunkerque
Dunkirk, France
-
CH Meaux
Meaux, France
-
CH Versailles
Le Chesnay, France
-
CH argenteuil
Argenteuil, France
-
CH d'Annecy
Annecy, France
-
CH de Dieppe
Dieppe, France
-
CHU Bordeaux
Bordeaux, France
-
CHU CAEN
Caen, France
-
CHU Lille
Lille, France
-
CHU Lyon
Lyon, France
-
CHU Nice
Nice, France
-
CHU Rennes
Rennes, France
-
CHU angers
Angers, France
-
Hopital Bon secours
Metz, France
-
Hopital La Source
Orléans La Source, France
-
Hopital Necker
Paris, France
-
Hopital Purpan
Toulouse, France
-
Institut Bergonié
Bordeaux, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.